AlloVir Stock Forecast, Price & News

+0.65 (+2.95 %)
(As of 06/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume300,018 shs
Average Volume316,696 shs
Market Capitalization$1.48 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ALVR News and Ratings via Email

Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter.

AlloVir logo

About AlloVir

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.


AlloVir (NASDAQ:ALVR)  Shares Down 5.7%
AlloVir (NASDAQ:ALVR) Shares Down 5.7%
June 8, 2021 |
Head-To-Head Review: AlloVir (ALVR) versus Its Peers
Head-To-Head Review: AlloVir (ALVR) versus Its Peers
June 7, 2021 |
AlloVir (ALVR) and Its Peers Head-To-Head Contrast
AlloVir (ALVR) and Its Peers Head-To-Head Contrast
June 2, 2021 |
AlloVir (NASDAQ:ALVR) Shares Gap Up to $23.44
AlloVir (NASDAQ:ALVR) Shares Gap Up to $23.44
June 1, 2021 |
Critical Comparison: AlloVir (ALVR) and Its Rivals
Critical Comparison: AlloVir (ALVR) and Its Rivals
June 1, 2021 |
AlloVir (NASDAQ:ALVR) Shares Up 6%
AlloVir (NASDAQ:ALVR) Shares Up 6%
May 28, 2021 |
AlloVir (ALVR) versus Its Rivals Critical Survey
AlloVir (ALVR) versus Its Rivals Critical Survey
May 25, 2021 |
10. ElevateBio - CNBC
10. ElevateBio - CNBC
May 25, 2021 |
Financial Analysis: AlloVir (ALVR) vs. The Competition
Financial Analysis: AlloVir (ALVR) vs. The Competition
May 24, 2021 |
AlloVir (NASDAQ:ALVR) Trading Up 7.4%
AlloVir (NASDAQ:ALVR) Trading Up 7.4%
May 20, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.67 out of 5 stars

Medical Sector

350th out of 2,100 stocks

Biological Products, Except Diagnostic Industry

49th out of 198 stocks

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

AlloVir (NASDAQ:ALVR) Frequently Asked Questions

Is AlloVir a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AlloVir stock.
View analyst ratings for AlloVir
or view top-rated stocks.

What stocks does MarketBeat like better than AlloVir?

Wall Street analysts have given AlloVir a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AlloVir wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is AlloVir's next earnings date?

AlloVir is scheduled to release its next quarterly earnings announcement on Wednesday, September 1st 2021.
View our earnings forecast for AlloVir

How were AlloVir's earnings last quarter?

AlloVir, Inc. (NASDAQ:ALVR) released its quarterly earnings results on Wednesday, May, 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.10.
View AlloVir's earnings history

What price target have analysts set for ALVR?

4 brokerages have issued 1-year price targets for AlloVir's shares. Their forecasts range from $42.00 to $55.00. On average, they anticipate AlloVir's stock price to reach $49.25 in the next twelve months. This suggests a possible upside of 117.0% from the stock's current price.
View analysts' price targets for AlloVir
or view top-rated stocks among Wall Street analysts.

Who are AlloVir's key executives?

AlloVir's management team includes the following people:
  • Mr. David L. Hallal, Chairman & CEO (Age 55, Pay $981.02k)
  • Mr. Vikas Sinha, Pres, CFO & Director (Age 58, Pay $654.9k)
  • Dr. Ercem Atillasoy M.D., Chief Regulatory & Safety Officer (Age 57, Pay $572.46k)
  • Mr. Brett R. Hagen, Chief Accounting Officer (Age 48)
  • Dr. Ann M. Leen Ph.D., Chief Scientific Officer (Age 44)
  • Ms. Medha Chadha M.B.A., Sr. VP of Strategic Planning & Investor Relations
  • Mr. Edward Miller, Gen. Counsel & Sec. (Age 56)
  • Dr. Jeroen Van Beek Ph.D., Chief Commercial Officer (Age 57)
  • Mr. Agustin Melian M.D., Chief Medical Officer & Head of Global Medical Sciences (Age 57)
  • Mr. Ugo Capolino Perlingieri, Head & GM of Europe and Middle East Operations

Who are some of AlloVir's key competitors?

What other stocks do shareholders of AlloVir own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD), Cloudera (CLDR), Infinera (INFN), Sonos (SONO), Trevena (TRVN), Abbott Laboratories (ABT), The Boeing (BA), Delta Air Lines (DAL), Datadog (DDOG) and FuelCell Energy (FCEL).

When did AlloVir IPO?

(ALVR) raised $252 million in an initial public offering on Thursday, July 30th 2020. The company issued 14,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

What is AlloVir's stock symbol?

AlloVir trades on the NASDAQ under the ticker symbol "ALVR."

Who are AlloVir's major shareholders?

AlloVir's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.64%), Redmile Group LLC (2.99%), Woodline Partners LP (1.81%), Alliancebernstein L.P. (1.69%), American International Group Inc. (1.55%) and Massachusetts Financial Services Co. MA (0.94%). Company insiders that own AlloVir stock include Agustin Melian, Ann M Leen, Beek Jeroen B Van, Brett R Hagen, Diana Brainard, Edward Miller, John Robert Wilson and Juan Vera.
View institutional ownership trends for AlloVir

Which institutional investors are selling AlloVir stock?

ALVR stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, TCW Group Inc., Credit Suisse AG, and Massachusetts Financial Services Co. MA. Company insiders that have sold AlloVir company stock in the last year include Agustin Melian, Ann M Leen, Beek Jeroen B Van, Brett R Hagen, Edward Miller, John Robert Wilson, and Juan Vera.
View insider buying and selling activity for AlloVir
or view top insider-selling stocks.

Which institutional investors are buying AlloVir stock?

ALVR stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Goldman Sachs Group Inc., Woodline Partners LP, Geode Capital Management LLC, American International Group Inc., Citigroup Inc., and Northern Trust Corp. Company insiders that have bought AlloVir stock in the last two years include Beek Jeroen B Van, and Diana Brainard.
View insider buying and selling activity for AlloVir
or or view top insider-buying stocks.

How do I buy shares of AlloVir?

Shares of ALVR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AlloVir's stock price today?

One share of ALVR stock can currently be purchased for approximately $22.70.

How much money does AlloVir make?

AlloVir has a market capitalization of $1.48 billion and generates $170,000.00 in revenue each year. The company earns $-69,780,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis.

How many employees does AlloVir have?

AlloVir employs 53 workers across the globe.

What is AlloVir's official website?

The official website for AlloVir is

Where are AlloVir's headquarters?

AlloVir is headquartered at 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142.

How can I contact AlloVir?

AlloVir's mailing address is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-433-2605 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.